The FDA has approved first-line pembrolizumab for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer.
Original Article: FDA Approves Frontline Pembrolizumab Regimen for Squamous NSCLC